Sustained release Exendin-4 Reduces Neurodegeneration in Parkinson’s Rat Model, Study Shows

Sustained release Exendin-4 Reduces Neurodegeneration in Parkinson’s Rat Model, Study Shows
0
(0)

A new long-lasting formulation of exendin-4, called PT302, reduced neurodegeneration in a rat model of Parkinson’s disease, according to new data from a preclinical study by Peptron.

The study, “Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease,” was published in Scientific Reports.

Parkinson’s disease is a chronic and progressive neurodegenerative disorder, mainly caused by the gradual loss of dopaminergic neurons in the substantia nigra, a region of the brain responsible for movement control.

Exendin-4, a peptide that activates the glucagon-like peptide-1 (GLP-1) receptor, is a hormone originally discovered in the saliva of the Gila monster. Previous studies have already shown that pre-treatment with exendin-4 significantly reduced dopaminergic neurodegeneration.

These promising results led researchers to propose GLP-1 receptor agonists as a new treatment option for several neurodegenerative diseases, including Parkinson’s, Alzheimer’s, Huntington’s, traumatic brain injury, stroke, and peripheral neuropathy.

However, the use of exendin-4 to treat patients with Parkinson’s has been severely hampered by the medication’s short half-life.

As a result, investigators at Peptron developed a new sustained release formulation of exenatide (marketed as Byetta and Bydureon) — a synthetic version of exendin-4 — called PT302, that extends the medication’s lifetime in the body.

“We are proud to apply our decades of experience in developing sustained-release therapeutics to the great unmet medical need of millions of people around the world who suffer from Parkinson’s disease,” Ho-Il Choi, PhD, CEO and director of Peptron, said in a press release.

In this preclinical study, researchers tested the effectiveness of PT302 in a rat model of Parkinson’s disease. First, they observed that a single under-the-skin administration of PT302 was able to sustain the levels of exendin-4 in the plasma of adult rats for more than 20 days.

Then, to determine a clinically relevant dose within this range, rats received PT302 once every two weeks, either before or following a lesion performed on one side of the brain. Remarkably, pre- and post-treatment with PT302 successfully reduced methamphetamine-induced rotation, a measure of brain lesion severity, after lesioning.

Post-lesion treatment with PT302 significantly increased brain tyrosine hydroxylase immunoreactivity (TH-IR) — a readout of dopaminergic neurons’ activity — in the substantia nigra and striatum on the lesioned side of the brain. Moreover, researchers found a direct correlation between the levels of exendin-4 in the plasma and TH-IR in the lesioned substantia nigra and striatum.

These findings indicate that post-treatment with PT302 sustains the levels of exendin-4 for longer periods of time and reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson’s disease at a clinically relevant dose.

“The peer-review and publication of this data is an important step in confirming the ability of our novel SR-exenatide drug to cross the blood-brain barrier and deliver long-acting therapeutic effects of the neuroprotective peptide. We are looking forward to beginning our Phase 2 clinical trial in Parkinson’s disease and advancing a novel therapeutic that could fight neurodegeneration,” Choi said.

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
×
Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Latest Posts
  • MCP-1 levels
  • drug delivery system
  • CDNF trial results
  • LRRK2 protein study

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?